esanum Interview: Improvement of cardiovascular risk factors

To date, no pharmacological agent to support weight loss has convincingly demonstrated cardiovascular safety in a rigorous clinical trial, said Erin A. Bohula May in an esanum interview during the ESC 2018.

Erin A. Bohula May interviewed at the ESC 2018 on improving cardiovascular risk factors through weight loss.

• Weight loss can improve cardiovascular (CV) risk factors but is difficult to achieve and maintain.

• To date, no pharmacological agent to support weight loss has convincingly demonstrated cardiovascular safety in a rigorous clinical trial and instead caused CV or psychiatric side effects.

• The current study by Bohula EA et al (2018) now shows that Lorcaserin is the first pharmacological agent for weight loss with proven safety in severe cardiovascular events.